Editor-in-Chief
Hatice Kübra Elçioğlu
Vice Editors
Levent Kabasakal
Esra Tatar
Online ISSN
2630-6344
Publisher
Marmara University
Frequency
Bimonthly (Six issues / year)
Abbreviation
J.Res.Pharm.
Former Name
Marmara Pharmaceutical Journal
Journal of Research in Pharmacy
2023 , Vol 27 , Issue Supp.
CORE SHELL TYPE LIPID POLYMER HYBRID NANOCARRIERS AS A NOVEL-GENERATION DRUG DELIVERY PLATFORM
1Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Türkiye
DOI :
10.29228/jrp.500
The main reason why nano-sized drug delivery systems are approached with
increasing interest in the field of science is to increase the therapeutic efficacy and
reduce the incidence of side effects by enabling drugs to be targeted. With the advent
of nanotechnology, many carrier systems - from inorganic based gold nanoparticles
to organic based lipid or polymeric nanoparticles - have been designed and
significant developments have been achieved in terms of their use in the treatment of
various diseases thanks to intense scientific investments. However, these scientific
developments in nanoscale drug delivery systems do not mean that there are definite
treatment regimens for many diseases, especially cancer. Because, while any drug
delivery system has many advantages, it also suffers from certain structural
limitations. Therefore, novel and hybrid systems, defined as integrated systems, have
been developed to highlight the advantages and overcome its limitations of each
system. Based on this understanding, lipid polymer hybrid nanoparticles, combining
liposomes and polymeric nanoparticles, emerged as a core shell structure in which
the polymeric core is covered with a phospholipid layer. These integrated systems
have attracted great interest in the academic community because they combine the
biomimetic characteristics of liposomes and the architectural advantages of
polymeric nanoparticles in their structures [1]. The general production techniques of
this novel generation drug delivery nano-sized systems are categorized into two
groups as single-step techniques and double-step techniques. Many physicochemical
characterization controls such as drug loading, particle size, morphological
properties, surface charge, drug release, lipid-shell thickness, interface chemical
composition, lipid shell fluidity, and lipid shell transition analyses are used to
characterize the core shell type lipid polymer hybrid nanoparticles. For in vitro
biological characterization of these integrated systems, cellular uptake and
cytotoxicity analyses are utilized as basic in vitro assays to assess effectiveness of
drug encapsulated hybrid particles against target cells prior to in vivo evaluations
[1,2]. Reviewing the applications of core shell type lipid polymer hybrid nanosystems
in the field of biomedicine, it becomes clear that they play an important role in the
treatment of various disorders, especially cancer [3,4]. Despite these technological
advances in core shell type hybrid systems, there are still serious obstacles to their
clinical use. The most serious of these is that the current laboratory-scale production
methods used for their production are not suitable for scale-up. In order to overcome
these limitations, it is necessary to develop production technologies that are suitable or adaptable for commercial production with a multidisciplinary approach and
serious cooperation.
Keywords :
Core shell structure, lipid polymer hybrid nanocarriers, drug delivery